Press Releases

Press Releases

COVID-19 Update from Samsung Biologics

A message from Tae Han Kim, CEO

 

The COVID-19 pandemic continues to escalate globally. Beyond the million plus diagnosed with the novel coronavirus, the daily lives of even more have been affected across the globe. Businesses and global events have been profoundly impacted with announcements of postponement, conversion to virtual, or cancellation. 

 

South Korea's COVID-19 response

 

South Korea is now seeing a steady trend in the daily decline of confirmed cases. This relatively fast and sustained recovery has been lauded by world health experts and attributed to many factors, which include: 

 

  • Early and decisive actions to expedite regulatory approval of test kits
  • Technology and infrastructure to trace and track infections with full transparency
  • Access to over 600 nationwide testing sites with a total capacity of up to 20,000 per day
  • Risk categorization of confirmed patients to optimize treatment capacity and options
  • Early and aggressive social campaigns to promote physical distancing and ways to prevent virus transmission

 

Our Employee Safety and Business Continuity

 

As we shared in our press release in March, Samsung Biologics has since January, been operating under our Business Continuity Plan, with a dedicated COVID-19 response team in place comprised of cross-functional members supported by senior executives. The countermeasures already in place include: 

 

  • Constant monitoring and maintaining of employee and visitor safety, our number one priority
  • Proactive management of our global supply chain
  • Daily disinfection of critical and high traffic areas
  • Enforcement of physical distancing and usage of preventative measures including facemasks and sanitizers at all times
  • Ongoing risk assessment of all facets of client impacting services to prevent potential business disruption

 

 

In addition to the actions taken above, our COVID-19 response team is actively monitoring global trends and emerging information to ensure that we continuously adapt our approach and take precautionary steps to ensure the safety of our workforce and continuous business operations for our clients.

 

This global crisis also reinforces the importance of outsourcing biopharmaceutical capabilities for patients, and the value that contract development and manufacturing partners provide. Samsung Biologics is determined to demonstrate our capabilities at this critical juncture and further the trust our clients have placed in us. From our accelerated cell line development services to our blockbuster capacity to rapidly scale to our clients’ manufacturing demands, Samsung Biologics is ready and poised to be the partner of choice in the fight against COVID-19.

 

Our Enhanced Virtual Capabilities for Client Communication

 

To facilitate our client communications, we have put in place virtual capabilities and convenient solutions to bridge the physical distance amidst global travel restrictions. We offer to our existing and prospective clients an array of innovative technologies including telepresence, immersive virtual reality, and interactive augmented reality to conduct facilities due diligence and virtual face-to-face meetings.

 

While the global fight against COVID-19 is far from over, rest assured that Samsung Biologics is taking every step to fulfill our mission to help make life saving medicines more accessible to everyone on earth – a purpose truly with meaning and relevance now more than ever.

 

Sincerely,

 

Tae Han Kim

 

Return to Our Dedicated COVID-19 Response Page  

 

A message from Tae Han Kim, CEO

 

The COVID-19 pandemic continues to escalate globally. Beyond the million plus diagnosed with the novel coronavirus, the daily lives of even more have been affected across the globe. Businesses and global events have been profoundly impacted with announcements of postponement, conversion to virtual, or cancellation. 

 

South Korea's COVID-19 response

 

South Korea is now seeing a steady trend in the daily decline of confirmed cases. This relatively fast and sustained recovery has been lauded by world health experts and attributed to many factors, which include: 

 

  • Early and decisive actions to expedite regulatory approval of test kits
  • Technology and infrastructure to trace and track infections with full transparency
  • Access to over 600 nationwide testing sites with a total capacity of up to 20,000 per day
  • Risk categorization of confirmed patients to optimize treatment capacity and options
  • Early and aggressive social campaigns to promote physical distancing and ways to prevent virus transmission

 

Our Employee Safety and Business Continuity

 

As we shared in our press release in March, Samsung Biologics has since January, been operating under our Business Continuity Plan, with a dedicated COVID-19 response team in place comprised of cross-functional members supported by senior executives. The countermeasures already in place include: 

 

  • Constant monitoring and maintaining of employee and visitor safety, our number one priority
  • Proactive management of our global supply chain
  • Daily disinfection of critical and high traffic areas
  • Enforcement of physical distancing and usage of preventative measures including facemasks and sanitizers at all times
  • Ongoing risk assessment of all facets of client impacting services to prevent potential business disruption

 

 

In addition to the actions taken above, our COVID-19 response team is actively monitoring global trends and emerging information to ensure that we continuously adapt our approach and take precautionary steps to ensure the safety of our workforce and continuous business operations for our clients.

 

This global crisis also reinforces the importance of outsourcing biopharmaceutical capabilities for patients, and the value that contract development and manufacturing partners provide. Samsung Biologics is determined to demonstrate our capabilities at this critical juncture and further the trust our clients have placed in us. From our accelerated cell line development services to our blockbuster capacity to rapidly scale to our clients’ manufacturing demands, Samsung Biologics is ready and poised to be the partner of choice in the fight against COVID-19.

 

Our Enhanced Virtual Capabilities for Client Communication

 

To facilitate our client communications, we have put in place virtual capabilities and convenient solutions to bridge the physical distance amidst global travel restrictions. We offer to our existing and prospective clients an array of innovative technologies including telepresence, immersive virtual reality, and interactive augmented reality to conduct facilities due diligence and virtual face-to-face meetings.

 

While the global fight against COVID-19 is far from over, rest assured that Samsung Biologics is taking every step to fulfill our mission to help make life saving medicines more accessible to everyone on earth – a purpose truly with meaning and relevance now more than ever.

 

Sincerely,

 

Tae Han Kim

 

Return to Our Dedicated COVID-19 Response Page  

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION